<DOC>
	<DOCNO>NCT01058408</DOCNO>
	<brief_summary>RAD001 approve U.S Food Drug Administration ( FDA ) treat advance kidney cancer . This drug also use research study evaluate effectiveness cancer . Information research study suggest RAD001 may help decrease growth development tumor cell reduce blood supply tumor need grow . In research study , try determine safety RAD001 give people locally advanced head neck cancer combination cisplatin radiation . We also look high dose RAD001 give people safely .</brief_summary>
	<brief_title>RAD001 With Weekly Cisplatin Radiation Therapy Patients With Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>- Most patient receive treatment head neck cancer develop difficulty swallow food drinking liquid course therapy . For reason , recommend PEG ( percutaneous endoscopic gastrostomy ) tube place participant stomach prior undergo study regimen . This help maintain weight nutritional health . - Since look high dose study drug administer safely without severe unmanageable side effect , everyone participates receive dose RAD001 cisplatin . - The study regimen last seven week . During week study participation follow occur : Radiation administer weekday ( 5 day per week ) . Cisplatin give intravenously start week . RAD001 give participant take home . Participants take study drug day morning start day 1 . - A history physical exam perform weekly participant 's receiving radiation treatment . Blood test routine laboratory testing perform weekly . - Each month first two month participant finish radiation therapy stop take RAD001 cisplatin , physical ezam , neurologic exam , blood test . X-rays , CT , MRI and/or PET scan also perform two month visit . After first two month , follow-up continue every 1-2 month first year . Additionally , every 6 month first two year , follow-up visit include assessment speech swallow function along X-rays , CT , MRI and/or PET scan .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients stage III/IV , locally advanced , biopsy proven squamous cell cancer head neck plan undergo chemoradiation primary treatment curative intent . Patients oropharynx , hypopharynx , larynx primary , nasopharynx well document SCC cervical lymph node , unknown primary , eligible . Patients must least evaluable disease one measurable site disease accord RECIST criterion desirable . 18 year age old Minimum two week since major surgery WHO performance status 2 less Adequate bone marrow , liver , renal function outline protocol Presence distant metastatic disease Prior chemotherapy Prior radiation head neck adjacent anatomical site Chronic treatment systemic steroid another immunosuppressive agent Patients receive immunization attenuate live vaccine within one week study entry study period Other malignancy within past 3 year except adequately treat carcinoma thyroid , cervix basal squamous cell carcinoma skin Patients severe and/or uncontrolled medical condition condition could affect participation study Uncontrolled diabetes mellitus A known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 Patients active , bleed diathesis oral antivitamin K medication Women pregnant breastfeeding , women/men able conceive unwilling practice effective method birth control Patients receive prior treatment mTOR inhibitor Patients know hypersensitivity RAD001 rapamycins excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>advanced head neck cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>RAD001</keyword>
	<keyword>radiation</keyword>
	<keyword>HNSCC</keyword>
</DOC>